Condition: Aneurysmal Subarachnoid Hemorrhage · Delayed Cerebral Ischemia · Sponsor: University of Florida
In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
This description comes directly from the study's public registry record.
Brian Hoh, MD · 352-273-9000 · brian.hoh@neurosurgery.ufl.edu
Always discuss trial participation with your own doctor first.
| University of Florida Health (UF Health) | Gainesville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06863480